Industry Insights Seminar Series: Targeting the Aryl Hydrocarbon Receptor (AHR) as a novel immunotherapy for the treatment of cancer

2 February @ 12:00 pm - 1:30 pm
Loading Events

« All Events

  • This event has passed.

This session of the Industry Insights Seminar Series will be presented by Dr Ilona Gutcher – Group Leader Oncology, Bayer AG.

To register, please use the ‘select a date’ button
2 FEBRUARY 2021: Targeting the Aryl Hydrocarbon Receptor (AHR) as a novel immunotherapy for the treatment of cancer

Presenter: Ilona Gutcher – Group Leader Oncology, Bayer AG.

Abstract: Current approved cancer immunotherapy treatments focus on stimulating anti-tumor T cell responses with antibodies against PD1/PD-L1 and CTLA4. However, tumor cells can also evade immune responses by upregulating tryptophan-degrading enzymes like indole-2,3-dioxygenase (IDO1) and tryptophan-2,3-dioxygenase (TDO2) to generate the immunosuppressive metabolites kynurenine (KYN) and kynurenic acid (KA). KYN and KA bind and activate the aryl hydrocarbon receptor (AhR), which is expressed in many cell types and is well known for its broad immunosuppressive effects. Targeting the AhR with an inhibitor may therefore provide a novel immunotherapeutic approach for enhancing anti-tumoral immune responses and treating cancer.

Here we describe for the discovery and functional characterization of the first-in-class small molecule AhR inhibitor BAY 2416964. BAY 2416964 is a novel, selective and potent inhibitor of AhR that inhibits nuclear translocation of AhR and its ensuing transcriptional activity. In vitro, BAY 2416964 stimulates the pro-inflammatory activity of human T cells and KA-suppressed monocytes. In vivo, BAY 2416964 treatment inhibits tumor growth in CT26 and B16-OVA syngeneic tumor models, the latter demonstrating increases in CD8+ T cells and NK cells, and decreases in suppressive myeloid cells, in the tumor microenvironment.

Based on promising pre-clinical data, a first-in-human phase I clinical trial was initiated in 2019 in patients with advanced solid malignancies to investigate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of BAY 2416964 (CT.gov NCT04069026). Exploratory analyses include assessment of human PK; evaluation of target engagement; assessment of immune cell markers in the tumor microenvironment and profiling of an AhR gene signature. Dose escalation of BAY 2416964 is currently ongoing.

 

Details

Date:
2 February
Time:
12:00 pm - 1:30 pm
Website:
Book now

Venue

Online

Latest news

Ludmila Milla, founder of UJJI

Ludmila Milla, founder of UJJI

Ludmila Milla is the founder of UJJI, a platform supporting its users in actively but securely working towards their goals Learn more

The First Questions to Ask Yourself when You have that Big Idea Part 1

The First Questions to Ask Yourself when You have that Big Idea Part 1

Dr Stuart Wilkinson gives advice on business ideas and how to manage them. Learn more

What is Intellectual Property (IP)?

What is Intellectual Property (IP)?

What you need to know about the ownership of your idea. Learn more

Danae Maragouthakis, Founder and CEO of Yoxly

Danae Maragouthakis, Founder and CEO of Yoxly

Danae is a medical doctor with a background in public health and member of BASHH (British Association for Sexual Health and HIV). She co-founded and is the CEO of Yoxly, a venture that provides a range of remote sexual health services through an ecosystem designed to give users more convenience, privacy, accessibility, and control. Learn more

Dr Assia Kasdi, Post-Doctoral Researcher at the University of Oxford and CEO of Milvus Advanced limited

Dr Assia Kasdi, Post-Doctoral Researcher at the University of Oxford and CEO of Milvus Advanced limited

Dr Assia Kasdi is a Post-doctoral researcher at the University of Oxford who pioneered a nano-material catalyst made of Earth-abundant materials. The material behaves like platinum and acts as a nano-catalyst for hydrogen electrolysis and fuel cells. Learn more

Louis Wright, Founder of OxBikes

Louis Wright, Founder of OxBikes

Louis is a 4th year student at Trinity college studying Materials Science and he has founded a start up called OxBikes: a bicycle ... Learn more

Carrie Lomas, CEO of EYFSHome and Brand Conscience

Carrie Lomas, CEO of EYFSHome and Brand Conscience

Carrie Lomas runs two ‘purpose with profit’ companies, one in EdTech (educational technology) and the other in sustainability for retail, which connects consumers to their buying choices. Learn more

Enterprising Oxford

Tell us a bit about yourself and see information and resources relevant to your needs.

Get in touch

10 + 6 =

Copyright © 2020 Enterprising Oxford | Site by Herd